|
**Overview**: Bone Marrow Examination 2 Panel**Introduction**: The Bone Marrow Examination 2 Panel is a diagnostic tool designed for comprehensive bone marrow evaluation using bone marrow samples. In India, comprehensive marrow analysis is crucial for diagnosing anemias, leukemias, lymphomas, and myelodysplasias (high burden in hematological malignancies). High morbidity from underdiagnosis in rural areas, limited advanced labs, delayed targeted therapy. Per hematology practices aligned with ICMR guidelines, the test employs microscopy, automated counter, iron stain, and detailed morphology over 1-2 days with high accuracy, valuable for full marrow assessment. This diagnostic falls under bone marrow screening and targets patients with complex cytopenias or malignancy suspicion, addressing accurate evaluation to guide chemotherapy or supportive care. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing mortality. Its bone marrow-based approach ensures reliable detection.**Other Names**: BM Exam Pnl 2.**FDA Status**: FDA approved, CLIA certified for hematology, compliant with 2025 standards.**Historical Milestone**: Comprehensive marrow exam standard; in India, essential in cancer centers.**Purpose**: The test evaluates 33 parameters including total cell count and iron stain to guide comprehensive marrow assessment, diagnose disorders.**Test Parameters**: 1. Total Cell Count, 2. Differential Count, 3. Myeloid/Erythroid Ratio, 4. Iron Stain, 5-33. Morphology and Cytology Parameters.**Pretest Condition**: No fasting required; patients should report cytopenias, fatigue, bleeding, or malignancy suspicion.**Specimen**: 1 mL bone marrow in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 24 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 48 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred).**Medical History**: Patients should provide details on cytopenias, symptoms, family hematological history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated disorders, benefits of evaluation, and discomfort from aspiration.**Procedural Considerations**: The test involves sample processing using microscopy and automated counter by trained personnel to ensure sterile technique and interpret results within 1-2 days. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low sample volume can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal findings indicate marrow disorder, necessitating specialist input. Normal may require follow-up if suspicion persists.**Specialist Consultation**: Hematologists should be consulted for management.**Additional Supporting Tests**: Flow cytometry, cytogenetics for confirmation.**Test Limitations**: May miss focal lesions; comprehensive approach required.**References**: Indian Journal of Hematology 2024, Bone Marrow Studies India 2023. |
